Preclinical trials will be conducted to test promising neuroprotectants. Trials will be translated to phase II/III trials in infants at high risk of cerebral palsy.

Members of the team have performed successful preclinical trials (e.g. melatonin) that are informing new trials in clinical populations. Neuroprotectants ready for implementation in human clinical trials include Erythropoietin (EPO), and Cord blood.  International multisite clinical trials of EPO and Stem cells between US, Australia and Europe are being developed for infants with neonatal stroke with optimal rehabilitation.


Current Projects in this theme: